DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
MDT logo

Medtronic plc Stock Price

NYSE:MDT Community·US$117.2b Market Cap
  • 7 Narratives written by author
  • 6 Comments on narratives written by author
  • 323 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

MDT Share Price Performance

US$90.96
-3.07 (-3.26%)
​
US$98.00
Fair Value
US$90.96
-3.07 (-3.26%)
7.2% undervalued intrinsic discount
US$98.00
Fair Value
Price US$90.96
AnalystConsensusTarget US$98.00
LunaRodas US$115.38
Evangelos US$95.00
Fri, 26 Jun 26
Fair ValueUS$98.00
Share Pricen/a

MDT Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$98 7.2% undervalued intrinsic discount

Robotic Surgery And Digital Health Will Shape Leadership In Global Markets

4users have liked this narrative
1users have commented on this narrative
155users have followed this narrative
LU
LunaRodas
LunaRodas's
Fair Value
·
Fair Value US$115.38 21.2% undervalued intrinsic discount

MDT | Medtronic: What They Said vs. What They Did

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
EV
Evangelos's
Fair Value
·
Fair Value US$95 4.3% undervalued intrinsic discount

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

11users have liked this narrative
5users have commented on this narrative
37users have followed this narrative
MDT logo
Medtronic
Fairly Valued intrinsic discount

Strong in favor of diversity in value portfolio

View narrative
SI
Silvester
Silvester
Published 17 Jun
Read Narrative
MDT logo
Medtronic
21.2% undervalued intrinsic discount

MDT | Medtronic: What They Said vs. What They Did

View narrative
LU
LunaRodas
LunaRodas
Published 1 Sep
Read Narrative
MDT logo
Medtronic
4.3% undervalued intrinsic discount

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

View narrative
EV
Evangelos
Published 14 Feb 2025
Read Narrative
MDT logo
Medtronic
10.0% overvalued intrinsic discount

MDT Market Outlook

View narrative
NA
NateF
Published 4 Jan 2025
Read Narrative
MDT logo
Medtronic
7.2% undervalued intrinsic discount

Robotic Surgery And Digital Health Will Shape Leadership In Global Markets

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 26 Jun
Read Narrative
MDT logo
Medtronic
7.0% overvalued intrinsic discount

Electrophysiology And Robotic Surgery Expansion Will Shape Steady Long Term Outlook

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
MDT logo
Medtronic
24.8% undervalued intrinsic discount

Medtronic Stock Will Rely On Cardiac Ablation Platforms To Drive A Stronger Future

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 19 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

LU
LunaRodas
MDT logo

MDT | Medtronic: What They Said vs. What They Did

Fair Value: US$115.38 21.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
SI
Silvester
MDT logo

Strong in favor of diversity in value portfolio

Fair Value: US$90.37 Fairly Valued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
EV
MDT logo

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Fair Value: US$95 4.3% undervalued intrinsic discount
37 fair values setusers have set this as their fair value
5 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Established dividend payer and good value.

0 Risks
5 Rewards
View Full Analysis

Medtronic plc Key Details

US$37.5b

Revenue

US$13.0b

Cost of Revenue

US$24.5b

Gross Profit

US$19.3b

Other Expenses

US$5.2b

Earnings

Last Reported Earnings
Jul 31, 2026
Next Reporting Earnings
n/a
4.09
65.27%
13.93%
55.3%
View Full Analysis

About MDT

Founded
1949
Employees
95000
CEO
Geoffrey Martha
WebsiteView website
www.medtronic.com

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Recent MDT News & Updates

User avatar
Narrative Update • Sep 03

MDT: Cardiovascular Momentum And Robotics Investment Will Shape Balanced Medium Term Outlook

Medtronic's analyst fair value estimate has moved from $78 to $85 as analysts factor in higher Street price targets, supported by stronger cardiovascular performance, Cardiac Ablation Solutions momentum, and product driven upside reflected in recent research updates. Analyst Commentary Recent Street research on Medtronic shows a generally constructive tone, with several firms lifting price targets following the latest quarterly results and guidance update.

Recent updates

No updates

Medtronic plc Competitors

UNH logo

UnitedHealth Group

Symbol: NYSE:UNH
Market cap: US$348.5b
ABT logo

Abbott Laboratories

Symbol: NYSE:ABT
Market cap: US$178.9b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$127.3b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$121.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide